Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Crinetics Pharmaceuticals Inc's Business Segments
Crinetics Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 11
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 11 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Product96%
- License and Service4%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 10 | 96% |
| License and Service | $ 0 | 4% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California. The company is focused on developing novel therapeutics for endocrine disorders and endocrine-related tumors. Crinetics was founded in 2008 by Dr. Stephen Betz, Dr. Scott Struthers, and Dr. Yunzhao Wei.
Crinetics is primarily engaged in designing and developing small molecule therapeutics that target peptide hormone receptors, such as the pituitary receptors for growth hormone-releasing hormone (GHRH), thyrotropin-releasing hormone (TRH), and corticotropin-releasing factor (CRF). These receptors are involved in a variety of physiological processes and have great potential for therapeutic intervention.
The company's lead product candidate is CRN00808, an orally available nonpeptide small molecule designed to selectively bind and activate the CRF type 2 receptor (CRF2). This receptor plays a key role in stress-related disorders, including anxiety, depression, and PTSD. By modulating the CRF2 receptor, CRN00808 aims to provide a novel approach for treating these disorders.
In addition to CRN00808, Crinetics has developed other product candidates targeting different hormone receptors. CRN01941, for example, is being developed for the treatment of acromegaly, a hormonal disorder characterized by excessive growth hormone production. The company's pipeline also includes product candidates for the treatment of congenital adrenal hyperplasia, Cushing's disease, neuroendocrine tumors, and other endocrine-related disorders.
Crinetics employs a multidisciplinary approach to drug discovery and development, combining expertise in medicinal chemistry, biology, pharmacology, and clinical research. The company's scientists utilize advanced technologies and computational methods to identify and optimize drug candidates that possess high selectivity, potency, and pharmacokinetic properties.
In order to advance its drug candidates through preclinical and clinical development, Crinetics collaborates with academic institutions, contract research organizations (CROs), and other industry partners. The company has also received funding support from various sources, including grants from the National Institutes of Health (NIH) and partnerships with pharmaceutical companies.
Overall, Crinetics Pharmaceuticals Inc. is dedicated to developing innovative and effective therapeutics for endocrine disorders and endocrine-related tumors. Its focus on targeting hormone receptors with small molecule drugs has the potential to revolutionize the treatment options available for patients suffering from these conditions.
Crinetics is primarily engaged in designing and developing small molecule therapeutics that target peptide hormone receptors, such as the pituitary receptors for growth hormone-releasing hormone (GHRH), thyrotropin-releasing hormone (TRH), and corticotropin-releasing factor (CRF). These receptors are involved in a variety of physiological processes and have great potential for therapeutic intervention.
The company's lead product candidate is CRN00808, an orally available nonpeptide small molecule designed to selectively bind and activate the CRF type 2 receptor (CRF2). This receptor plays a key role in stress-related disorders, including anxiety, depression, and PTSD. By modulating the CRF2 receptor, CRN00808 aims to provide a novel approach for treating these disorders.
In addition to CRN00808, Crinetics has developed other product candidates targeting different hormone receptors. CRN01941, for example, is being developed for the treatment of acromegaly, a hormonal disorder characterized by excessive growth hormone production. The company's pipeline also includes product candidates for the treatment of congenital adrenal hyperplasia, Cushing's disease, neuroendocrine tumors, and other endocrine-related disorders.
Crinetics employs a multidisciplinary approach to drug discovery and development, combining expertise in medicinal chemistry, biology, pharmacology, and clinical research. The company's scientists utilize advanced technologies and computational methods to identify and optimize drug candidates that possess high selectivity, potency, and pharmacokinetic properties.
In order to advance its drug candidates through preclinical and clinical development, Crinetics collaborates with academic institutions, contract research organizations (CROs), and other industry partners. The company has also received funding support from various sources, including grants from the National Institutes of Health (NIH) and partnerships with pharmaceutical companies.
Overall, Crinetics Pharmaceuticals Inc. is dedicated to developing innovative and effective therapeutics for endocrine disorders and endocrine-related tumors. Its focus on targeting hormone receptors with small molecule drugs has the potential to revolutionize the treatment options available for patients suffering from these conditions.
Crinetics Pharmaceuticals, Inc. specializes in the development and commercialization of innovative therapeutics, specifically targeting endocrine diseases and disorders. The company focuses on advancing its proprietary product candidates based on a deep understanding of hormonal signaling and its associated mechanisms.
Segments
1. Endocrine Disorders: This is the core segment of Crinetics business, where the primary focus lies on treatments for diseases related to hormonal imbalances. The company aims to address conditions such as acromegaly, Cushings disease, and other hormone-related disorders.
2. Rare Diseases: Crinetics has a strong commitment to developing drugs for rare endocrine diseases. This segment involves targeting conditions that may not be as common but still require effective therapeutic options due to their significant impact on patient quality of life.
3. Therapeutic Areas: Crinetics concentrates on defined therapeutic areas where hormone-related pathways play a critical role. This includes not only endocrine disorders but also related areas such as oncology, where hormonal manipulation can be clinically relevant.
Products
1. Paltusotine (CRN04894): This is Crinetics lead product candidate, a selective, orally administered somatostatin receptor type 2 (SST2) agonist designed to inhibit growth hormone secretion in patients with acromegaly. Clinical trials have shown its potential to reduce growth hormone levels and improve patient outcomes.
2. CRN01941: This investigational drug is aimed at treating patients with Cushings disease. CRN01941 is an oral small molecule designed to target a specific mechanism in the cortisol-overproduction pathway, offering a novel approach to managing this debilitating condition.
3. Selected Peptide Therapies: Crinetics is also exploring additional peptide therapies aimed at various endocrine disorders. These products are still in the developmental phase but are targeted to enhance the treatment landscape for hormonal imbalances.
4. CRN06383: Another promising candidate under development, this product aims to address disorders associated with excessive cortisol levels. Specific indications and therapeutic mechanisms are still being explored in clinical trials.
5. Preclinical Candidates: Beyond its advanced clinical-stage programs, Crinetics is actively developing other preclinical compounds that target various endocrine dysfunctions, showcasing their commitment to expanding their pipeline in the endocrine therapeutics field.
Services
Crinetics Pharmaceuticals does not traditionally offer services like a contract research organization or service-based model but provides extensive clinical and regulatory expertise in the development of endocrine therapeutics. Some of the indirect services they may provide include:
1. Clinical Development Expertise: With a focus on clinical trials, Crinetics capitalizes on its deep understanding of endocrine disorders to design and execute trials that meet stringent regulatory standards.
2. Collaborative Partnerships: The company engages in strategic collaborations with academic institutions, research organizations, and partnerships across the biopharmaceutical sector to leverage insights and advance its pipeline.
3. Regulatory Affairs: Crinetics invests in regulatory affairs to navigate the complexities of FDA and EMA regulations, ensuring that its product candidates meet necessary safety and efficacy requirements.
4. Market Access and Commercial Readiness: As products approach the market, Crinetics invests resources to ensure that they are prepared for commercialization, which includes identifying market access strategies and pricing models to maximize patient access.
Conclusion
Crinetics Pharmaceuticals, Inc. operates in a highly specialized niche within the pharmaceutical industry, focusing on innovative treatments for endocrine disorders. By identifying underserved patient populations and engaging in robust R&D, Crinetics aims to develop effective therapeutic options that address significant unmet medical needs. Through its pipeline of product candidates, the company combines scientific expertise with strategic business development to position itself as a leader in the endocrine therapeutic space.
Segments
1. Endocrine Disorders: This is the core segment of Crinetics business, where the primary focus lies on treatments for diseases related to hormonal imbalances. The company aims to address conditions such as acromegaly, Cushings disease, and other hormone-related disorders.
2. Rare Diseases: Crinetics has a strong commitment to developing drugs for rare endocrine diseases. This segment involves targeting conditions that may not be as common but still require effective therapeutic options due to their significant impact on patient quality of life.
3. Therapeutic Areas: Crinetics concentrates on defined therapeutic areas where hormone-related pathways play a critical role. This includes not only endocrine disorders but also related areas such as oncology, where hormonal manipulation can be clinically relevant.
Products
1. Paltusotine (CRN04894): This is Crinetics lead product candidate, a selective, orally administered somatostatin receptor type 2 (SST2) agonist designed to inhibit growth hormone secretion in patients with acromegaly. Clinical trials have shown its potential to reduce growth hormone levels and improve patient outcomes.
2. CRN01941: This investigational drug is aimed at treating patients with Cushings disease. CRN01941 is an oral small molecule designed to target a specific mechanism in the cortisol-overproduction pathway, offering a novel approach to managing this debilitating condition.
3. Selected Peptide Therapies: Crinetics is also exploring additional peptide therapies aimed at various endocrine disorders. These products are still in the developmental phase but are targeted to enhance the treatment landscape for hormonal imbalances.
4. CRN06383: Another promising candidate under development, this product aims to address disorders associated with excessive cortisol levels. Specific indications and therapeutic mechanisms are still being explored in clinical trials.
5. Preclinical Candidates: Beyond its advanced clinical-stage programs, Crinetics is actively developing other preclinical compounds that target various endocrine dysfunctions, showcasing their commitment to expanding their pipeline in the endocrine therapeutics field.
Services
Crinetics Pharmaceuticals does not traditionally offer services like a contract research organization or service-based model but provides extensive clinical and regulatory expertise in the development of endocrine therapeutics. Some of the indirect services they may provide include:
1. Clinical Development Expertise: With a focus on clinical trials, Crinetics capitalizes on its deep understanding of endocrine disorders to design and execute trials that meet stringent regulatory standards.
2. Collaborative Partnerships: The company engages in strategic collaborations with academic institutions, research organizations, and partnerships across the biopharmaceutical sector to leverage insights and advance its pipeline.
3. Regulatory Affairs: Crinetics invests in regulatory affairs to navigate the complexities of FDA and EMA regulations, ensuring that its product candidates meet necessary safety and efficacy requirements.
4. Market Access and Commercial Readiness: As products approach the market, Crinetics invests resources to ensure that they are prepared for commercialization, which includes identifying market access strategies and pricing models to maximize patient access.
Conclusion
Crinetics Pharmaceuticals, Inc. operates in a highly specialized niche within the pharmaceutical industry, focusing on innovative treatments for endocrine disorders. By identifying underserved patient populations and engaging in robust R&D, Crinetics aims to develop effective therapeutic options that address significant unmet medical needs. Through its pipeline of product candidates, the company combines scientific expertise with strategic business development to position itself as a leader in the endocrine therapeutic space.